Business Context and Reporting Period
This Form 8-K was filed by ImmunityBio, Inc. on February 7, 2025. The report details compensation arrangements approved by the Compensation Committee for the company's Named Executive Officers (NEOs): Dr. Patrick Soon-Shiong (Founder, Executive Chairman, and Global Chief Scientific and Medical Officer), Richard Adcock (CEO and President), and David Sachs (CFO).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation.
- 2024 Cash Bonuses: Total approved bonuses for NEOs sum to $1,080,343, representing 80% of the target amount under the 2024 bonus plan. Payment is scheduled for approximately March 14, 2025.
- 2025 Equity Awards: Granted on February 10, 2025, vesting ratably over 3 years.
- 2025 Base Salaries: Effective March 10, 2025, total annual base salaries for the three NEOs sum to $2,080,469.
Material Changes
The filing reports the following specific changes to executive compensation effective in 2025:
- Base Salary Adjustments: New annual base salary rates were established for all three NEOs, effective March 10, 2025.
- Equity Grants: New RSU and stock option awards were granted on February 10, 2025, with an exercise price of $3.39 per share (equal to the closing price on the grant date).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The only commentary provided relates to the Compensation Committee's assessment that the company achieved pre-established performance measures for 2024, resulting in an 80% payout of target bonuses.
Investor Verification Checklist
- Verify the total cash outflow of approximately $1.08 million for 2024 bonuses payable in March 2025.
- Confirm the dilution impact of 4,468,136 new stock options and 1,891,446 RSUs granted to executives.
- Review the 2025 base salary increases totaling $2.08 million annually for the three NEOs.
- Check the vesting schedule (3-year ratable vesting) for the new equity awards to understand future expense recognition.